Creative Medical Technology Holdings vs Lyell Immunopharma
Lyell Immunopharma is the larger business, with $36,000 of revenue in fiscal 2025 against $6,000 for Creative Medical Technology Holdings (6.0 times as much). Lyell Immunopharma grew faster (-41.0% against -45.5%). Creative Medical Technology Holdings kept more of each dollar of sales as profit: a net margin of -99916.8% against -762355.6%. Creative Medical Technology Holdings carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | Creative Medical Technology HoldingsCELZ, 2025 | Lyell ImmunopharmaLYEL, 2025 |
|---|---|---|
| Revenue | $6,000 | $36,000 |
| Revenue growth | -45.5% | -41.0% |
| Net income | −$6.0m | −$274m |
| Operating margin | -102380.2% | -748344.4% |
| Net margin | -99916.8% | -762355.6% |
| Return on equity | -86.5% | -87.0% |
| Free cash flow | — | −$151m |
| Cash | $7.2m | $60.2m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | $10,000 | — |
| Employees | — | 161 |
| Market value | $4.3m | $252m |
| Price vs our value range | — | — |
| Moat score | 35 (Weak) | 12 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 2 buys, 29 sales |